key: cord-0809394-fy7kuzru authors: Adomi, Motohiko; Kuno, Toshiki; Komiyama, Jun; Taniguchi, Yuta; Abe, Toshikazu; Miyawaki, Atsushi; Imai, Shinobu; Morita, Kojiro; Saito, Makoto; Ohbe, Hiroyuki; Kamio, Tadashi; Tamiya, Nanako; Iwagami, Masao title: Association between pre‐admission anticoagulation and in‐hospital death, venous thromboembolism, and major bleeding among hospitalized COVID‐19 patients in Japan date: 2022-04-07 journal: Pharmacoepidemiol Drug Saf DOI: 10.1002/pds.5433 sha: 91a6075d000c6b4a44d5612cba0dd2c297bc3082 doc_id: 809394 cord_uid: fy7kuzru PURPOSE: The coagulation activation leads to thrombotic complications such as venous thromboembolism (VTE) in patients with coronavirus disease‐2019 (COVID‐19). Prophylactic anticoagulation therapy has been recommended for hospitalized COVID‐19 patients in clinical guidelines. This retrospective cohort study aimed to examine the association between pre‐admission anticoagulation treatment and three outcomes: in‐hospital death, VTE, and major bleeding among hospitalized COVID‐19 patients in Japan. METHODS: Using a large‐scale claims database built by the Medical Data Vision Co. in Japan, we identified patients hospitalized for COVID‐19 who had outpatient prescription data at least once within 3 months before being hospitalized. Exposure was set as pre‐admission anticoagulation treatment (direct oral anticoagulant or vitamin K antagonist), and outcomes were in‐hospital death, VTE, and major bleeding. We conducted multivariable logistic regression analyses, adjusting for a single summarized score (a propensity score of receiving pre‐admission anticoagulation) for VTE and major bleeding, due to the small number of outcomes. RESULTS: Among the 2612 analytic patients, 179 (6.9%) had pre‐admission anticoagulation. Crude incidence proportions were 13.4% versus 8.5% for in‐hospital death, 0.56% versus 0.58% for VTE, and 2.2% versus 1.1% for major bleeding among patients with and without pre‐admission anticoagulation, respectively. Adjusted odds ratios (95% confidence intervals) were 1.25 (0.75–2.08) for in‐hospital death, 0.21 (0.02–1.97) for VTE, and 2.63 (0.80–8.65) for major bleeding. Several sensitivity analyses did not change the results. CONCLUSIONS: We found no evidence that pre‐admission anticoagulation treatment was associated with in‐hospital death. However, a larger sample size may be needed to conclude its effect on VTE and major bleeding. • We found no association between pre-admission anticoagulation and the outcomes. The results from this study neither recommend nor discourage pre-admission anticoagulation among hospitalized COVID-19 patients. • A larger sample size may be needed to conclude the effect of pre-admission anticoagulation on venous thromboembolism and major bleeding. Excessive activation of coagulation is well-known in patients with coronavirus disease-2019 and it manifests as occlusion of blood vessels in the lower limb or lung. Blood thinners are the medication to prevent the formulation of blood clots and have been used for hospitalized COVID-19 patients. However, blood thinners sometimes cause bleeding in the digestive tract or brain and need careful monitoring. This study examined the effect of blood thinners, which were started before COVID-19 hospitalization, on in-hospital death, blood vessels occlusion, and bleeding. Statistical analyses found that pre-admission blood thinners intake was not associated with any of these events. The results suggest that blood thinners initiation before hospitalization neither benefit nor harm patients' survival. Because there were not enough patients who had blood vessels occlusion and bleeding in this study, a larger study is necessary. Coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2, was first reported in Wuhan, China, in December 2019. 1 The global pandemic of COVID-19 has infected nearly 300 million people, with 5 million deaths up to early January 2022. 2 Previous studies have reported the occurrence of coagulopathies in patients with COVID-19, [3] [4] [5] leading to venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), which may precipitate critical conditions. Considering the physiological features, prophylactic anticoagulation, thromboprophylaxis with subcutaneous low-molecular-weight heparin, or unfractionated heparin has been suggested for use in patients hospitalized with COVID-19. [6] [7] [8] The association between pre-admission anticoagulation treatment for a pre-existing condition (such as atrial fibrillation [AF] and deep vein thrombosis [DVT] ) and patient outcomes of COVID-19 has been investigated. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] These studies were conducted under the hypothesis that pre-admission anticoagulation therapy may mitigate the hypercoagulation physiology of COVID- 19 . However, as summarized in Table S1 , conflicting results have been reported. About half the previous studies reported null results for the association between pre-admission anticoagulation with direct oral anticoagulant (DOAC) or vitamin K antagonist (VKA) and in-hospital mortality. 9, 11, 12, 14, [18] [19] [20] Although there are beneficial aspects of anticoagulation, concerns have arisen with regard to bleeding events with therapeutic anticoagulation. One study reported an increased odds ratio of major or clinically relevant nonmajor bleeding among patients with COVID-19 receiving therapeutic doses of anticoagulation treatment compared to those receiving prophylactic doses of anticoagulation treatment. 21 As shown in Table S2 , several studies showed a higher incidence of bleeding events in patients with pre-admission anticoagulation treatment than in those without pre-treatment. 11, 16, 19, 20 Given the conflicting data from previous studies, clinical practitioners need more information to decide whether pre-admission anticoagulation treatment should be maintained or terminated. Herein, we examined this hypothesis among patients hospitalized with COVID-19 in Japan, in terms of three outcomes: in-hospital death, VTE, and major bleeding. This study was a retrospective cohort study conducted using the insurance claims database of Medical Data Vision Co., Ltd. (MDV). The MDV database consists of inpatient, outpatient, and pharmacy claims from over 350 hospitals, including more than 30 million people, 23% of the total population in Japan. 22 We analyzed data obtained between January 1, 2020 and December 31, 2020. In the MDV database, identification numbers were assigned to each hospitalization episode, instead of to each patient. Because of the structure of this data, previous outpatient visits of hospitalized patients, the necessary information to measure the exposure, could only be identified if they visited the same hospital where they were hospitalized for COVID-19. Patients were included in this study if they met the following inclusion criteria: First, for data availability, patients were hospitalized with an admission diagnosis of COVID-19 and discharged by December 31, 2020; Second, the reimbursements of newly introduced financial incentives for COVID-19 were recorded for the patient. In April 2020, the Japanese government introduced incentives to make additional payments to hospitals if they treated hospitalized patients with COVID- 19. 23 Since laboratory polymerase chain reaction (PCR) test results for COVID-19 were unavailable in the database, we used these incentives to narrow the study population to patients whose diagnosis of COVID-19 was plausible. Third, the patients' outpatient prescription data from the same hospital was identified within 3 months before admission. The 3-month look back period was adopted because a long-term prescription is usually limited to a maximum of 3 months for each outpatient visit in Japan. This period was long enough to measure and classify exposure status in the current Japanese healthcare system. Throughout the study, we set pre-admission anticoagulation treatment, a prescription of anticoagulants within 3 months before hospital admission due to COVID-19, as an exposure of interest. Anticoagulants were defined as one of the following DOACs or VKA, which are available in Japan: dabigatran, rivaroxaban, apixaban, edoxaban, and warfarin. The prescription of anticoagulants was identified using the Anatomical Therapeutic Chemical Classification System (ATC) codes corresponding to the drugs (dabigatran: B01AE07, rivaroxaban: B01AF01, apixaban: B01AF02, edoxaban: B01AF03, warfarin: B01AA03). 24 We defined the outcomes in this study as in-hospital death, VTE, 25 In-hospital death was identified by hospital discharge outcome records, and the incidence of VTE and major bleeding were identified by diagnosis codes during hospitalization. The diagnosis codes of VTE and bleeding have been validated in the MDV database, with a positive predictive value (PPV) of 75% for VTE and 73% for major bleeding. 26 In-hospital death has also been validated with a PPV of 96% using the other claims database in Japan. 27 F I G U R E 1 Flow of the population selection We considered the following variables as potential confounders in this study: age, sex, body mass index (BMI), smoking history, comorbidities (cancer, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease, atrial fibrillation), immunosuppressant use, and history of VTE. We utilized the claims data until the first day of hospital admission for each patient to retrieve these covariates. Comorbidities We described the baseline characteristics of patients with and without pre-admission anticoagulation. The proportions of outcomes were crudely described by pre-admission anticoagulation status. We then conducted multivariable logistic regression analyses to compare patients with and without pre-admission anticoagulation treatment for the three outcomes. For in-hospital death, we adjusted for the aforementioned covariates. For VTE and major bleeding, because of the small number of outcomes, we adjusted for a single summarized score, namely, the propensity score of receiving pre-admission anticoagulation treatment. The propensity score was calculated using all the aforementioned covariates in a multivariable logistic regression model. For all statistical analyses, missing data on BMI and smoking history were imputed using multiple imputation by chained equations using all the variables, including the outcomes. 28 Additionally, we conducted two sensitivity analyses for in-hospital death. First, we restricted the study population to individ- analysis to increase the comparability of people who had received pre-admission anticoagulation treatment and those who did not. We identified the information on CVD using claims data until the first day of hospital admission. Second, we limited the study population to patients who did not change the anticoagulation strategy before and during hospitalization (i.e., patients with pre-admission anticoagulation and who continued anticoagulation during hospitalization, and patients without pre-admission anticoagulation and who did not initiate anticoagulation treatment during hospitalization), and conducted multivariable regression analysis for the association between preadmission anticoagulation treatment and in-hospital death. This sensitivity analysis was conducted because in-hospital anticoagulation treatment may also affect patient outcomes. In this retrospective cohort study, we examined the association between pre-admission anticoagulation therapy and three outcomes, among patients hospitalized with COVID-19. We did not find any statistically significant difference in the association between preadmission anticoagulation treatment and in-hospital death. The point estimates of odds ratios for VTE and major bleeding were in line with the biological mechanisms (i.e., low for VTE and high for major bleeding); however, there was no statistical significance. The sensitivity analyses did not influence the conclusions. To our knowledge, this is the first study in Japan to examine the association between pre-admission anticoagulation treatment with inhospital death, VTE, and major bleeding among hospitalized COVID-19 patients. The relative risk of in-hospital death found in this study (adjusted odds ratio: 1.25, 95% CI: 0.75-2.08) was consistent with some previous studies, which reported that there was no association between pre-admission anticoagulation therapy and mortality among patients hospitalized with COVID-19 shown in Table S1 . 9, 11, 12, 14, [18] [19] [20] For example, a propensity score-matched cohort study in the Netherlands showed that the odds ratio for all-cause in-hospital mortality was 1.02 (95% CI: 0.80-1.30) among patients with and without pre-admission anticoagulation treatment. 18 Similarly, a propensityscore matched cohort study in New York City showed that the hazard ratio for all-cause mortality was 1.208 (95% CI: 0.750-1.946), comparing hospitalized and ambulatory patients with and without preadmission anticoagulation treatment. 11 On the contrary, some studies showed that pre-admission anticoagulation treatment was associated with lower or higher probability of studied outcomes. 10 It is noteworthy that the in-hospital mortality rate observed in our study (8.8%) was lower compared to the previous studies referred above, in which in-hospital mortality ranged from 15.0% to 43.8%. However, the in-hospital mortality in our study seems feasible when compared to a previous study in Japan reporting in-hospital mortality rates of 9.6% 29 and 7.5%. 30 One possible explanation is that in Japan, there were milder cases of patients hospitalized with COVID-19. With regard to VTE, our results showed lower odds ratio of VTE among patients with pre-admission anticoagulation. Although this result did not reach statistical significance, the point estimate of odds ratio may indicate the protective effect of pre-admission anticoagulation. This result is in line with the result of some studies 18, 20 but is contrary to that of another. 11 As we observed small number of VTE incidence in our study population, we should not reach conclusive answer from this result. Notably, the incidence of VTE in this study was 0.4% (10/2612) for DVT and 0.3% (9/2612) for PE, and this is comparable to a previous study in Japan which reported an incidence proportion of 0.9% for DVT and 0.5% for PE. 30 On the other hand, the incidence proportion of VTE was lower compared to that of previous studies summarized in Table S2 , which ranged from 1.2% to 6.8%. 11, 18, 20 This was also lower than that reported in a previous meta-analysis, which mainly included the studies from Western countries (the pooled incidence proportions of PE and DVT were 16.5% and 14.8%, respectively). 31 A possible explanation for the lower incidence of VTE in our study population is that the proportion of hospitalized patients with mild disease was higher in Japan. In addition, there are several known risk factors for VTE, such as obesity, diabetes mellitus, and smoking. We consider that the proportion of these risk factors (especially obesity) for VTE was smaller in Japanese patients compared to patients in western countries. 32 With regard to major bleeding, our results showed a higher odds ratio for major bleeding among patients with pre-admission anticoagulation. Although this result did not reach statistical significance, the direction of the association between pre-admission anticoagulation and major bleeding is reasonable. This result is also in line with that of previous studies that reported a higher risk of bleeding in patients with pre-admission anticoagulation compared to those without (Table S2) . 11, 16, 19, 20 For example, one study in the United States reported that the incidence proportion was 3 (1.2%) versus 20 (0.57%) among patients with and without pre-admission anticoagulation treatment, respectively. 11 Regarding the risk of major bleeding among hospitalized patients with COVID-19, one metaanalysis that included five studies reported that the pooled incidence proportion was 3.9% (95% CI, 1.2-7.9) for major bleeding. 33 The incidence proportion in our study (1.2%) was comparable to that reported in these studies. Previous studies have indicated that increased production of inflammatory cytokines and vascular endothelium damage causes coagulopathy in patients with COVID-19. 34, 35 Accordingly, it is biologically plausible to hypothesize that anticoagulation during hospitalization may decrease the incidence rates of VTE or mitigate the severity of coagulopathy and lead to lower mortality among patients. Since coagulation activation may have occurred before hospitalization, it is conceivable that pre-admission anticoagulation treatment may confer lower mortality. However, the analyses showed no difference in VTE and in-hospital death among patients with and without preadmission anticoagulation treatment. Because the effect of in-hospital anticoagulation treatment needs to be considered in our study, we conducted a sensitivity analysis comparing patients with pre-admission anticoagulation use who continued anticoagulation treatment after hospitalization, with patients without pre-admission anticoagulation who did not initiate anticoagulation therapy during hospitalization. The analysis showed that the observed association between pre-admission anticoagulation use and in-hospital death did not change, after considering in-hospital anticoagulation therapy. identified. Fourth, adherence to prescribed anticoagulants before hospitalization could not be considered in the analyses because the prescriptions were identified by the available prescription data. If many patients with pre-admission anticoagulation prescriptions were not adherent to the drug, the results would most likely be diluted to the null association between pre-admission anticoagulation treatment and the studied outcomes. Finally, our results with relatively wide confidence intervals showed a less precise estimate compared to the estimate we would have obtained had we included all the patients in the analyses. In summary, using a large-scale claims database from Japan, we examined the association between pre-admission anticoagulation treatment and in-hospital death, VTE, and major bleeding among hospitalized COVID-19 patients. No statistically significant differences were observed in the measured outcomes. We would like to thank employees in Medical Data Vision Co., Ltd., especially Masaki Nakamura and Shogo Atsuzawa, for their contribution to prepare for and interpretation of the claims data. We also thank Editage (www.editage.com) for English language editing. Atsushi Miyawaki has a joint research project with MDV outside of this study and is receiving labor contributions. None of other authors declare any conflict of interest. Motohiko Adomi designed this study, conducted data processing, ana- The ethics committee of The University of Tsukuba approved this study (approval number: 1624). Individual informed consent was waived because the claims data were deidentified using dummy identification numbers, before being made available to the researchers. https://orcid.org/0000-0003-4277-4509 Yuta Taniguchi https://orcid.org/0000-0002-0176-2379 Masao Iwagami https://orcid.org/0000-0001-7079-0640 Clinical features of patients infected with 2019 novel coronavirus in Wuhan Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study Incidence of venous thromboembolism in hospitalized patients with COVID-19 Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence Antithrombotic Therapy in Patients With COVID-19, National Institute of Health COVID-19 Treatment Guidelines Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19 Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study Oral anticoagulation and clinical outcomes in COVID-19: an Italian multicenter experience Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19 Direct oral anticoagulant use and risk of severe COVID-19 Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany The association of preinfection daily oral anticoagulation use and all-cause in hospital mortality from novel coronavirus 2019 at 21 days: a retrospective cohort study Anticoagulation before hospitalization is a potential protective factor for COVID-19: insight from a French multicenter cohort study Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: a propensity scorematched cohort study The Association of anticoagulation before admission and survival of patients with COVID-19 Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19 Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial Notifications from ministry of health, labor, and welfare with regard to additional payments toward treatment of COVID-19 patients World Health Organization's Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2021 The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study Incidence of venous thromboembolism and bleeding events in patients with lower extremity orthopedic surgery: a retrospective analysis of a Japanese healthcare database Validation of claims data to identify death among aged persons utilizing enrollment data from health insurance unions Using the outcome for imputation of missing predictor values was preferred Prevalence of thromboembolic events and status of prophylactic anticoagulant therapy in hospitalized patients with COVID-19 in Japan Clinical epidemiology of hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan: report of the COVID-19 registry Japan Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis Cardiovascular risk factors and venous thromboembolism: a meta-analysis Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis Coagulopathy in COVID-19 COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year ATTACC Investigators Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19 Therapeutic anticoagulation with heparin in critically ill patients with Covid-19 Validity of diagnoses, procedures, and laboratory data in Japanese administrative data Association between pre-admission anticoagulation and in-hospital death, venous thromboembolism, and major bleeding among hospitalized COVID-19 patients in Japan